Arnott, Clare

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 893

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 358

Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

Arnott, C., Li, Q., Kang, A., Neuen, B. L., Bompoint, S., Lam, C. S. P., Rodgers, A., Mahaffey, K. W., Cannon, C. P., Perkovic, V., et al. (2020) · Journal of the American Heart Association

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 247

Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L. (2020) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 130

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 115

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes

Neuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., Jun, M., Jardine, M. J., Zoungas, S., Pollock, C., et al. (2021) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 78

Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials

Fletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J. V., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., et al. (2023) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 40

Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

Barraclough, J. Y., Yu, J., Figtree, G. A., Perkovic, V., Heerspink, H. J. L., Neuen, B. L., Cannon, C. P., Mahaffey, K. W., Schutte, A. E., Neal, B., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPeripheral Artery Disease Management

Cited by 37